Latest news with #Lenalidomide
&w=3840&q=100)
Business Standard
02-07-2025
- Business
- Business Standard
Dr Reddy's expects US sales dip in FY26, aims for resilience via scale-up
Hyderabad-based pharmaceutical major Dr Reddy's Laboratories (DRL) has said it is prepared to address an anticipated decline in sales in the United States in FY26 through a combination of organic and inorganic strategies. In a joint message to stakeholders, DRL's chairman K Satish Reddy and co-chairman and managing director G V Prasad said one of the company's key products in the US will face increased competition starting February 2026, likely leading to a fall in sales and profits. 'We have been preparing for this through FY25, through a combination of organic and inorganic strategies,' the message added. DRL stated that in FY26, it aims to grow and strengthen its core businesses and enhance value through portfolio management and strategic differentiation. The company also plans to scale its presence in consumer healthcare, innovative therapies and biosimilars, introduce new revenue streams through acquisitions and partnerships, and streamline structural costs to cushion the impact. For FY25, DRL recorded a 17 per cent rise in total revenue from operations—from ₹27,916 crore in FY24 to ₹32,554 crore. According to the company's investor presentation, North America contributed 45 per cent of DRL's full-year revenue. 'In the US, growth was steady and matched market pace, supported by new launches, Lenalidomide sales, and a stable base business,' the company noted in its annual report filed with the exchanges. The drugmaker has been targeting a larger share of the US market through a dual-track strategy: reinforcing its core business of branded generics, biosimilars and over-the-counter (OTC) drugs, while also investing in growth areas such as consumer healthcare, biosimilars and novel molecules including new chemical entities (NCEs) and CAR-T therapies. 'Leveraging our distribution capabilities, we entered into a nutrition venture with Nestlé in India, received US rights for Cyclophosphamide from Ingenus, and launched Galvus (anti-diabetes) in Russia,' DRL said. The company also highlighted that its subsidiary, Aurigene, received US FDA approval for two oncology assets—AUR110 for solid tumours and AUR112 for lymphoid malignancies—and has filed for approval of the osteoporosis drug Denosumab in the US and Europe. 'These initiatives are in line with our strategy to address issues of availability and accessibility of affordable innovation through in-house and collaborative efforts,' the annual report stated. On Wednesday, DRL's share closed 0.41 per cent lower at ₹1,271.75 apiece on the Bombay Stock Exchange (BSE).
Mint
20-06-2025
- Business
- Mint
Stocks to trade today: Trade Brains Portal recommends two stocks for 20 June
Today, we recommend two stocks, one from the healthcare sector and the other from the railways sector. We also analyze the market's performance on Thursday to understand what may lie ahead for the stock indices in the coming days. Here are two stocks to trade today, as recommended by Trade Brains Portal Biocon Ltd (Current price: ₹349) Target price: ₹405 in 16-24 months Stop loss: ₹320 Why it's recommended: Founded in 1978, Biocon Ltd is the top biopharma firm in India, improving the lives of people in more than 120 countries by developing novel and cost-effective treatments for cancer, diabetes, and autoimmune diseases. The company employs more than 18,200 people who work in the research services, biosimilars, generics, and new biologics divisions. The largest integrated insulin manufacturing and research and development facility in Malaysia is operated by Biocon, which also contains one of the biggest biomanufacturing facilities for insulin, monoclonal antibodies, and devices. The group's four incubated businesses are Biocon Biologics, which focuses on biosimilars and accounts for 58% of total revenue in FY25; the generics division, which contributes 19%; and Syngene, which provides research services and accounts for 23% of total revenue in FY25. When comparing the performance on a like-for-like basis, revenue from operations totalled ₹15,262 crore, a 10% year-on-year increase; Ebitda reached ₹4,374 crore with a margin of 27%, and the net profit in FY25 was ₹1,013 crore, which represents a significant turnaround. The company has launched several new products, such as Liraglutide in the UK, Dasatinib in the US, and YesintekTM, which boosted revenue performance in Q4FY25. Going forward, the company plans to invest $200-250 million in capital expenditures across several business segments. While Syngene will increase the capacity of its research centres and production facilities for large and small compounds, BBL wants to expand its insulin factory in Malaysia as part of its capital expenditure plans. It is anticipated to spend $50 million in capital expenditures on generics in the upcoming year. The business anticipates approving generic Copaxone in the US and launching liraglutide there. According to management, Lenalidomide will be introduced in limitless quantities, with more launches scheduled for FY26. Additionally, five other products—Stelara, Bevacizumab, Aspart, Aflibercept, and Denosumab—will be introduced during the next 12 to 18 months. Risk Factor: If clearances from the US Food and Drug Administration, the European Medicines Agency, and those in the Asian and Latin American markets are delayed, their biosimilar business may miss out on opportunities. Additionally, the company faces fierce competition from a number of cost-competitive Indian enterprises as well as strong defense tactics from innovative companies that produce authorized generics. Also Read: Is the Israel-Iran war a billion-dollar threat to Adani Ports & SEZ? Titagarh Rail Systems Ltd (Current price: ₹839) Target price: ₹1,050 in 16-24 months Stop loss: ₹730 Why it's recommended: Titagarh Rail Systems was founded in 1997 and has over 25 years of expertise as a top provider of comprehensive mobility solutions in India. Its main activities include the production of passenger coaches, propulsion equipment, urban metros, semi-high-speed trains, and a variety of wagons, including specialized ones. With four production sites, the firm can now produce 12,000 wagons and 300 coaches annually, processing about 30,000 tonnes of casting steel. As of FY25, their entire order book was worth ₹11,200 crore. Titagarh Rail Systems is the only Indian company that produces both wagons and coaches. In FY25, operational revenue was ₹3,867 crore, a slight increase over ₹3,853 crore in FY24; however, it increased 18% CAGR since FY23. PAT stood at ₹274 crore, down 4.9% from ₹288 crore in FY24; however, it has been increasing at a robust CAGR of 43% since FY23. In FY25, the FRS segment's revenue was ₹3,610.27 crore, up 5.64% year over year. In FY25, the PRS segment's income was ₹255.55 crore. The company achieved a record for the most wagons ever produced in a single year in India, with 9,431 wagons. In FY25, it produced 27,240 metric tonnes in the foundry, setting a new production record. In order to increase its production to a significantly higher level in FY26, the company plans to expand its foundry by constructing fully modern foundry production facilities. About 40,000 tonnes of castings are what the company hopes to produce in the first phase of production in FY26. Since the supply chain problems with China have been fixed, the business anticipates that manufacturing for the Bangalore Metro will be rather streamlined. It is anticipated that production will be completely simplified starting in Q2 of FY26. Starting in FY26, the company plans to increase its propulsion division by between 125 and 150 traction motors every month, or 1,500 to 1,800 traction motors per month. The company has its sights set on winning a number of projects from the enormous potential pipeline. Among the major projects are the anticipated ₹15,800 crore Metro coach contracts and the ₹72,000 crore Vande Bharat Coach. Also Read: Is India's premium at risk? As Israel-Iran conflict sparks FPI outflows, valuation debate rages Risk Factor: More than 90% of the company's operating revenues come from freight rail systems and wagons, and Indian Railways continues to be the company's biggest source of sales. Additionally, geographically speaking, the company works on nearly all local projects and has little to no exposure to international enterprises. Market recap As the benchmark indices were flat amid the ongoing geopolitical worries that continued to worry investors, who remained vigilant, the Indian markets stayed flat and followed a bearish trend throughout the market hours on Thursday. The Nifty 50 hit an intraday low of 24,733.40 after opening at 24,803.25. Similar to this, the BSE Sensex opened at 81,403.94 and fell as low as 81,191.04 during the day. With an RSI of 51.65, the Nifty 50 closed at 24,793.25, down -18.80 points, or -0.08%, and fell below the 20-day EMA but above the 50/100/200 throughout the day. In contrast, the BSE Sensex closed below the 20-day EMA but above the 50/100/200 in the daily time frame at 81,361.87, down -82.79 points, or -0.10%, with an RSI of 50.50. The majority of sectoral indices ended in the red. One of the major losers was the Nifty PSU Bank Index, which ended the day at 6,734.30, down -140.35 points, or -2.04%. For three straight trading sessions, it saw a decrease. Additionally, it was touching the 50-day EMA and trading below the 20-day EMA. Almost all the companies declined in this index, with the Central Bank of India, Bank of India, Punjab & Sind Bank, UCO Bank, and Indian Overseas Bank among the major losers, dropping below 3% and causing the index to decline. Amid ongoing tensions between Israel and Iran, Asian markets likewise mirrored the pessimistic outlook on Thursday. For the fourth day in a row, the US Federal Reserve held the fed rate steady while cautioning that Donald Trump's trade policies would increase the danger of inflation. Hong Kong's Hang Seng index closed at 23,237.74, down -1.99%, or -472.95 points. The Nikkei 225 in Japan closed at 38,488.34, down -396.81 points, or -1.02%. At 10,051.97, the Shenzhen Index decreased -123.62 points, or -1.22%. The Shanghai index of China has likewise dropped, closing at 3,362.11, down -26.70 points, or -0.79%. The Kospi index for South Korea, meanwhile, increased slightly, ending at 2,977.74 after rising 0.19%, or 5.55 points. On Thursday, Dow Jones Futures in the US fell -173.60 points, or -0.42%, to 41,996. Also Read: Dull summer casts a cloud on Voltas's air conditioner volumes in Q1 Trade Brains Portal is a stock analysis platform. Its trade name is Dailyraven Technologies Pvt. Ltd, and its Sebi-registered research analyst registration number is INH000015729. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Yahoo
07-06-2025
- Business
- Yahoo
Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout
On May 31, 2025, Viatris Inc. (NASDAQ:VTRS) became the subject of a securities fraud class action lawsuit filed in the U.S. District Court for the Western District of Pennsylvania. The suit alleges that between August 8, 2024, and February 26, 2025, the company and certain executives made materially false or misleading statements regarding the operational status of its Indore, India manufacturing facility. Ralf Kleemann/ The complaint centers on Viatris' public assurances that its facilities were in "good operating condition" and committed to "the highest quality manufacturing standards." However, following a failed inspection, the U.S. Food and Drug Administration issued a Warning Letter and Import Alert in December 2024 that affected 11 products, including the cancer drug Lenalidomide. On February 27, 2025, Viatris (NASDAQ:VTRS) disclosed that the inspection issues would negatively impact 2025 revenue by roughly $500 million and earnings from operations by about $385 million. This revelation led to a 15% drop in Viatris' stock price, from $11.24 to $9.53 per share. Investors who purchased Viatris securities during the specified period have until June 3, 2025, to seek appointment as lead plaintiff in the lawsuit. While we acknowledge the potential of VTRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-06-2025
- Business
- Yahoo
Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout
On May 31, 2025, Viatris Inc. (NASDAQ:VTRS) became the subject of a securities fraud class action lawsuit filed in the U.S. District Court for the Western District of Pennsylvania. The suit alleges that between August 8, 2024, and February 26, 2025, the company and certain executives made materially false or misleading statements regarding the operational status of its Indore, India manufacturing facility. Ralf Kleemann/ The complaint centers on Viatris' public assurances that its facilities were in "good operating condition" and committed to "the highest quality manufacturing standards." However, following a failed inspection, the U.S. Food and Drug Administration issued a Warning Letter and Import Alert in December 2024 that affected 11 products, including the cancer drug Lenalidomide. On February 27, 2025, Viatris (NASDAQ:VTRS) disclosed that the inspection issues would negatively impact 2025 revenue by roughly $500 million and earnings from operations by about $385 million. This revelation led to a 15% drop in Viatris' stock price, from $11.24 to $9.53 per share. Investors who purchased Viatris securities during the specified period have until June 3, 2025, to seek appointment as lead plaintiff in the lawsuit. While we acknowledge the potential of VTRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Citizen
02-06-2025
- Health
- The Citizen
Local man fights rare cancer with hope and strength
Gregory Morgan from Kibler Park is facing the biggest challenge of his life after being diagnosed with a rare form of cancer. Morgan was diagnosed with multiple myeloma on February 28, 2022, at the Milpark Hospital. Now, he is asking for community support to help cover the high costs of life-saving treatment. A sudden turn 'Morgan's journey began in January 2022 when admitted to Mulbarton Hospital with a chest infection. During his stay, he contracted the Pseudomonas virus, a serious bacterial infection. Though treated and discharged, he soon returned with the same infection. During his stay, he picked up the pseudomonas virus, a serious bacterial infection. Although treated and discharged, he soon found himself back in the hospital with the same infection. 'I had a biopsy done on my lungs to check for cancer, but thankfully, it came back negative,' said Morgan. 'I was put on antibiotics and discharged again, but just a week later, I was back in the hospital.' On February 19, 2022, he was admitted to the Milpark Hospital in critical condition. 'I became extremely sick. My C-reactive protein (CRP) level was 591, so I was put in the ICU for nearly three weeks,' he said. Under the care of Dr PG Williams, further investigations revealed a possible diagnosis of multiple myeloma, a type of blood cancer. An oncologist later confirmed this after a bone marrow biopsy. Morgan began chemotherapy shortly afterwards and in April 2023, was approved for an autologous stem cell transplant. 'It works by using your healthy stem cells and is a 100% match. I didn't require a donor,' he explained. The first step involved harvesting his healthy stem cells, followed by a high-dose chemotherapy regimen to eliminate cancer cells. The stem cells were then re-infused, allowing them to migrate back into his bone marrow. Thereafter, his good stem cells were re-infused and migrated into his bone marrow. 'This was an unpleasant experience, but it also gave me hope for my recovery. After my transplant, I needed to continue with oral chemotherapy treatment for almost three years.' Unfortunately, in October last year, he suffered a relapse. Morgan was given stronger oral chemotherapy drugs and monitored by his oncologist monthly. At this time, he also suffered from severe back and nerve pain and had to have a spinal fusion, but couldn't while on chemotherapy. 'January this year, my cancer cells continued to increase. My oncologist advised me that I needed to start with a combination of even stronger chemotherapy. This devastating news again emotionally affected me. My chemo drugs were stopped for almost two months so I could have my spinal fusion procedure done on March 4,' explained Morgan. The fight begins He is now undergoing a new round of intense treatment, a combination of Ninlarb, Lenalidomide, and Neofordex, which he started in March. These medications are necessary to control cancer but come with a steep price. 'The cost of my current treatment is almost R50 000 monthly. My medical aid doesn't cover everything, and once the oncology benefit runs out, I have to pay the rest out of pocket,' he explained. His oncologist advised him that this treatment would be long-term, two to three years, with bone marrow biopsies every six months. Hope beyond donations Despite the hardships, Morgan remains hopeful and deeply motivated by his love for his family. 'What keeps me going is the hope of spending more time with my grandchildren. It's not just about me; it's about giving myself the best shot at life.' In a heartfelt plea, Morgan said he has always tried to be strong and handle things alone, but this diagnosis forced him to ask for help. 'The weight, physically, emotionally, and financially, became too heavy to carry by myself,' he said. 'Asking for help hasn't been easy, but it's necessary. If people in the community respond to my appeal, it would mean more than just financial help; it would mean hope,' emphasised Morgan. He wants to remind others facing battles that they are not alone. 'To anyone in a difficult season, I want to say: There is hope. You might feel like the weight is too heavy but know there is light on the other side. Hold onto hope with both hands.' As he continues his fight against cancer and with his faith in God and prayer, Morgan is making a heartfelt appeal to the public. 'I am personally asking for help,' he said. 'Your donation, no matter how small, can help me cover these costs and continue my fight against cancer.' With the support of the community, he hopes to alleviate the financial pressure so he can focus on his recovery and spend time with his loved ones. 'Your support would mean the world to me. If you're able to donate or even share my story, you'll be making a real difference in my life,' Morgan added. 'It's not just about the money. It's about giving me the strength to keep going and the chance to live a fulfilling life again.' Those wanting to support Morgan can visit his fundraising page or make a direct donation to: Discovery Bank; GN Morgan; Account No: 1832 7837 521; He is also running a Father's Day raffle, with prizes sponsored by Detailease. The details are on his Facebook and TikTok pages. Every act of kindness brings Morgan one step closer to hope and healing. At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
